The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Open accessAbstract
Background & aims Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage tumors, such as melanoma or lung cancer. We aimed to characterize molecular features of immune cells that infiltrate hepatocellular carcinomas (HCCs) to determine whether these types of agents might be effective against liver tumors.Methods We analyzed HCC samples from 956 patients. We separated gene expression profiles from tumor, stromal, and immune cells using a non-negative matrix factorization algorithm. We then analyzed the gene expression pattern of inflammatory cells in HCC tumor samples. We correlated expression patterns with the presence of immune cell infiltrates and immune regulatory molecules, determined by pathology and immunohistochemical analyses, in a training set of 228 HCC samples. We validated the correlation in a validation set of 728 tumor samples. Using data from 190 tumors in the Cancer Genome Atlas, we correlated immune cell gene expression profiles with numbers of chromosomal aberrations (based on single-nucleotide polymorphism array) and mutations (exome sequence data).Results We found approximately 25% of HCCs to have markers of an inflammatory response, with high expression levels of the CD274 molecule (programmed death-ligand 1) and programmed cell death 1, markers of cytolytic activity, and fewer chromosomal aberrations. We called this group of tumors the Immune class. It contained 2 subtypes, characterized by markers of an adaptive T-cell response or exhausted immune response. The exhausted immune response subclass expressed many genes regulated by transforming growth factor beta 1 that mediate immunosuppression. We did not observe any differences in numbers of mutations or expression of tumor antigens between the immune-specific class and other HCCs.Conclusions In an analysis of HCC samples from 956 patients, we found almost 25% to express markers of an inflammatory response. We identified 2 subclasses, characterized by adaptive or exhausted immune responses. These findings indicate that some HCCs might be susceptible to therapeutic agents designed to block the regulatory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or transforming growth factor beta 1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inflamed tumours constitute ~30% of HCCs and exhibit extensive immune cell infiltration and immune activity, detected as increased expression of immune checkpoints (such as PD-1 or its ligand PD-L1), activation of IFN signalling and a low burden of large chromosomal alterations70,71,78.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a high TMB does not correlate with increased immune infiltration70,71.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Flagged first, then by citations
2 of the 46 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 1,000
Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities
Kalasekar, S. M., Vansant-Webb, C. H., & Evason, K. J. (2021) · Cancers · doi:10.3390/cancers13215524 · Cited by 57
Chen, W., Ou, M., Tang, D., Dai, Y., & Du, W. (2020) · Journal of Immunology Research · doi:10.1155/2020/5494858 · Cited by 54
Yang, M., Lin, C.-H., Wang, Y., Chen, K., Zhang, H., & Li, W. (2022) · Genome Medicine · doi:10.1186/s13073-022-01079-x · Cited by 54
Pathologic and molecular features of hepatocellular carcinoma: An update
Vij, M., & Caldéraro, J. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i4.393 · Cited by 56
Zhang, T., Lei, X., Jia, W., Li, J., Nie, Y., Mao, Z., Wang, Y., Tao, K., & Song, W. (2022) · Cancer Medicine · doi:10.1002/cam4.5227 · Cited by 53
Nishida, N. (2021) · Cancers · doi:10.3390/cancers13153666 · Cited by 56
Nguyen, C. T., Caruso, S., Maille, P., Bèaufrere, A., Augustin, J., Favre, L., Pujals, A., Boulagnon‐Rombi, C., Rhaiem, R., Amaddeo, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1219 · Cited by 55
Atezolizumab plus Bevacizumab — A Landmark in Liver Cancer
Kelley, R. K. (2020) · New England Journal of Medicine · doi:10.1056/nejme2004851 · Cited by 53
Rhee, H., Kim, H., & Park, Y. N. (2020) · Liver Cancer · doi:10.1159/000510522 · Cited by 52
Zang, M., Li, Y., He, H., Ding, H., Chen, K., Du, J., Chen, T., Wu, Z., Liu, H., Wang, D., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.004 · Cited by 51
Fujii, Y., Ono, A., Hayes, C. N., Aikata, H., Yamauchi, M., Uchikawa, S., Kodama, K., Teraoka, Y., Fujino, H., Nakahara, T., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02016-3 · Cited by 49
Hong, S., Xie, Y., Cheng, Z., Li, J., He, W., Guo, Z., Zhang, Q., Peng, S., He, M., Yu, S., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02499-0 · Cited by 49
Chen, K., Wu, Z., Zhao, H., Wang, Y., Ge, Y., Wang, D., Li, Z., An, C., Liu, Y., Wang, F., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0210 · Cited by 49
Lorenzo, S. D., Tovoli, F., & Trevisani, F. (2022) · Cancers · doi:10.3390/cancers14194616 · Cited by 53
Precision models in hepatocellular carcinoma
Bárcena‐Varela, M., Monga, S. P., & Lujambio, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01024-w · Cited by 57
Zhou, J., Wang, W., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01873-2 · Cited by 50
Tu, Y., Wu, H., Zhong, C., Liu, Y., Xiong, Z., Chen, S., Wang, J., Wong, P. P.-C., Yang, W., Liang, Z., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332281 · Cited by 50
Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma
Maestri, E., Kedei, N., Khatib, S. A., Forgues, M., Ylaya, K., Hewitt, S. M., Wang, L., Chaisaingmongkol, J., Ruchirawat, M., Ma, L., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000600 · Cited by 46
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Martin, E. D., Fulgenzi, C. A. M., Celsa, C., Laurent-Bellue, A., Torkpour, A., Lombardi, P., D’Alessio, A., & Pinato, D. J. (2024) · Gut · doi:10.1136/gutjnl-2024-332125 · Cited by 51
Immune Therapy for Liver Cancers
Hilmi, M., Vienot, A., Rousseau, B., & Neuzillet, C. (2019) · Cancers · doi:10.3390/cancers12010077 · Cited by 46
Advances in Histological and Molecular Classification of Hepatocellular Carcinoma
Choi, J. H., & Thung, S. N. (2023) · Biomedicines · doi:10.3390/biomedicines11092582 · Cited by 52
Self-citationDynamics of Genomic, Epigenomic, and Transcriptomic Aberrations during Stepwise Hepatocarcinogenesis
Jee, B. A., Choi, J. H., Rhee, H., Yoon, S., Kwon, S. M., Nahm, J. H., Yoo, J. E., Jeon, Y., Choi, G. H., Woo, H. G., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0991 · Cited by 45
Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma
Chan, S. L., Wong, L.-L., Chan, K. C. A., Chow, C., TONG, J. H. M., Yip, T. C., Wong, G. L., Chong, C. C. N., Liu, P., Chu, C.-M., et al. (2019) · Liver Cancer · doi:10.1159/000504252 · Cited by 46
Zaki, M. Y. W., Fathi, A. M., Samir, S., Eldafashi, N., William, K. Y., Nazmy, M., Fathy, M., Gill, U. S., & Shetty, S. (2022) · Cancers · doi:10.3390/cancers14051255 · Cited by 49
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 43
Hepatotoxicity of immune check point inhibitors: Approach and management
Lleò, A., Rimassa, L., & Colombo, M. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.06.017 · Cited by 44
Huang, M., He, M., Guo, Y., Li, H., Shen, S., Xie, Y., Li, X., Xiao, H., Fang, L., Li, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3840 · Cited by 42
Wang, H., Jiang, Y., Li, B., Cui, Y., Li, D., & Li, R. (2020) · Cancers · doi:10.3390/cancers12123562 · Cited by 42
The Endless Sources of Hepatocellular Carcinoma Heterogeneity
Bárcena‐Varela, M., & Lujambio, A. (2021) · Cancers · doi:10.3390/cancers13112621 · Cited by 43
Human-correlated genetic models identify precision therapy for liver cancer
Müller, M., May, S., Hall, H., Kendall, T. J., McGarry, L., Blukacz, L., Nuciforo, S., Γεωργακοπούλου, Α., Jamieson, T., Phinichkusolchit, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08585-z · Cited by 40
Self-citationNew and old biomarkers of hepatocellular carcinoma
Zacharakis, G., Aleid, A., & Aldossari, K. K. (2018) · Hepatoma Research · doi:10.20517/2394-5079.2018.76 · Cited by 42
Tian, M., Liu, W.-R., Wang, H., Zhou, Y., Jin, L., Jiang, X., Tao, C.-Y., Tang, Z., Zhou, P., Fang, Y., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1341-6 · Cited by 41
Yamauchi, M., Ono, A., Amioka, K., Fujii, Y., Nakahara, H., Teraoka, Y., Uchikawa, S., Fujino, H., Nakahara, T., Murakami, E., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00390-x · Cited by 40
Harding, J. J., Khalil, D. N., & Abou‐Alfa, G. K. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05517-6 · Cited by 39
Liver Cancer: Current and Future Trends Using Biomaterials
Chew, S. A., Moscato, S., George, S., Azimi, B., & Danti, S. (2019) · Cancers · doi:10.3390/cancers11122026 · Cited by 40
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges
Teng, Y., Xie, S., Guo, P.-P., Deng, Z., Zhang, Z., Gao, W., Zhang, W., & Zhong, J. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00586 · Cited by 41
Li, Z., de Fromentel, C. C., Kim, W., Wang, W., Sun, J., Yan, B., Utturkar, S. M., Lanman, N. A., Elzey, B. D., Yeo, Y., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06302-0 · Cited by 38
Specific features of ß-catenin-mutated hepatocellular carcinomas
Dantzer, C., Dif, L., Vaché, J., Basbous, S., Billottet, C., & Moreau, V. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02849-7 · Cited by 42
Cheng, W., Li, H., Xi, S., Zhang, X., Zhu, Y., Xing, L., Mo, Y. D., Li, M.-M., Kong, F.-E., Zhu, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27525-9 · Cited by 39
Devan, A. R., Pavithran, K., Nair, B., Murali, M., & Nath, L. R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i36.5250 · Cited by 38
Characterization of the Immune Cell Infiltration Landscape in Esophageal Squamous Cell Carcinoma
Sui, Z., Wu, X., Du, L., Wang, H., Yuan, L., Zhang, J. V., & Yu, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879326 · Cited by 38
Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC
You, M., Gao, Y., Fu, J., Xie, R., Zhu, Z., Hong, Z., Meng, L., Du, S., Liu, J., Wang, F., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000369 · Cited by 39
Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment
Liu, Y., Yang, H., Li, T. X., & Zhang, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1460282 · Cited by 39
Second-line treatment options in hepatocellular carcinoma
Marino, D., Zichi, C., Audisio, M., Sperti, E., & Maïo, M. D. (2019) · Drugs in Context · doi:10.7573/dic.212577 · Cited by 37
Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma
von Felden, J., & Villanueva, A. (2020) · Liver Transplantation · doi:10.1002/lt.25731 · Cited by 38
Self-citationWang, S., Yuan, P., Mao, B., Li, N., Ying, J., Tao, X., Tang, W., Zhang, L., Geng, X., Zhang, F., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00244-6 · Cited by 38
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma
Muhammed, A., D’Alessio, A., Enica, A., TALBOT, T. L., Fulgenzi, C. A. M., Nteliopoulos, G., Goldin, R. D., Cortellini, A., & Pinato, D. J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2049244 · Cited by 35
Ou, D., Lin, Y., Hsu, C., Lin, Y., Chen, C., Yu, J.-S., Miaw, S., Hsu, P., Cheng, A., & Hsu, C. (2018) · Liver Cancer · doi:10.1159/000489318 · Cited by 35
Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma
Tauber, C., Schultheiß, M., Luca, R. D., Buettner, N., Llewellyn‐Lacey, S., Emmerich, F., Zehe, S., Price, D. A., Neumann‐Haefelin, C., Schmitt-Graeff, A. H., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27146 · Cited by 36
Nishida, N., & Kudo, M. (2020) · Cancers · doi:10.3390/cancers12051274 · Cited by 36
Hu, Z., Xin, H., Luo, C., Jia, L., Zhou, Z., Zou, J., & Zhou, S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02685-7 · Cited by 36
Cerapio, J., Marchio, A., Cano, L., López, I., Fournié, J., Regnault, B., Casavilca-Zambrano, S., Ruiz, E., Dejean, A., Bertani, S., et al. (2021) · OncoTarget · doi:10.18632/oncotarget.27890 · Cited by 28
β-Catenin Activation in Hepatocellular Cancer: Implications in Biology and Therapy
Krutsenko, Y., Singhi, A. D., & Monga, S. P. (2021) · Cancers · doi:10.3390/cancers13081830 · Cited by 36
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J., Chung, H. C., Lee, S.-H., Kim, D., Chun, S., Kim, J., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02034-1 · Cited by 36
Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
Maravelia, P., Silva, D. N., Rovesti, G., Chrobok, M., Stal, P. I., Lu, Y., & Pasetto, A. (2021) · Cancers · doi:10.3390/cancers13174334 · Cited by 38
Liu, X., Huangfu, Y., Wang, J.-R., Kong, P., Tian, W., Liu, P., Fang, C., Li, S., Nie, Y., Feng, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202300637 · Cited by 36
Morita, M., Nishida, N., Aoki, T., Chishina, H., Takita, M., Ida, H., Hagiwara, S., Minami, Y., Ueshima, K., & Kudo, M. (2023) · Cancers · doi:10.3390/cancers15082311 · Cited by 40
Grassberger, C., Hong, T. S., Hato, T., Yeap, B. Y., Wo, J. Y.-L., Tracy, M., Bortfeld, T. R., Wolfgang, J. A., Eyler, C. E., Goyal, L., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.04.026 · Cited by 35
Neoantigens as potential vaccines in hepatocellular carcinoma
Repáraz, D., Ruiz, M., Llópiz, D., Silva, L., Vercher, E., Aparicio, B., Egea, J., Tamayo, I., Hervás‐Stubbs, S., García-Balduz, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003978 · Cited by 34
Ji, J. H., Ha, S. Y., Lee, D., Sankar, K. N., Koltsova, E. K., Abou‐Alfa, G. K., & Yang, J. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087640 · Cited by 34
Wnt/β-Catenin Signaling in Liver Pathobiology
Carson, M. D., & Nejak‐Bowen, K. N. (2024) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023535 · Cited by 36
Nakamura, T., Masuda, A., Nakano, D., Amano, K., Sano, T., Nakano, M., & Kawaguchi, T. (2025) · Cells · doi:10.3390/cells14060428 · Cited by 43
Kurebayashi, Y., Kubota, N., & Sakamoto, M. (2020) · Hepatology Research · doi:10.1111/hepr.13539 · Cited by 35
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Kudo, M. (2020) · Liver Cancer · doi:10.1159/000512170 · Cited by 34
Raja, A., & Haq, F. U. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03826-w · Cited by 33
Yoon, J. K., Choi, J., Rhee, H., & Park, Y. N. (2022) · European Radiology · doi:10.1007/s00330-022-08643-4 · Cited by 34
Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives
Girardi, D. M., Sousa, L. P., Miranda, T. A., Haum, F. N. C., Pereira, G. C. D. B., & Pereira, A. A. L. (2023) · Cancers · doi:10.3390/cancers15061680 · Cited by 35
Nie, Y., Fan, H., Li, J., Lei, X., Zhang, T., Wang, Y., Mao, Z., Tao, K., & Song, W. (2022) · The FASEB Journal · doi:10.1096/fj.202200269rr · Cited by 32
Zhou, Y., Zhu, G., Lu, X., Zheng, K. I., Wang, Q.-W., Chen, J.-N., Zhang, Q., Yan, F., & Li, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02525-8 · Cited by 33
Nishida, N., Sakai, K., Morita, M., Aoki, T., Takita, M., Hagiwara, S., Komeda, Y., Takenaka, M., Minami, Y., Ida, H., et al. (2020) · Liver Cancer · doi:10.1159/000506352 · Cited by 36
Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
He, Y., Lu, M., Che, J., Chu, Q., Zhang, P., & Chen, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.716844 · Cited by 34
Meng, X., Xiong, Z., Xiao, W., Yuan, C., Wang, C., Huang, Y., Tong, J., Shi, J., Chen, Z., Liu, C., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.141 · Cited by 32
Akasu, M., Shimada, S., Kabashima, A., Akiyama, Y., Shimokawa, M., Akahoshi, K., Kudo, A., Yamaoka, S., Tanabe, M., & Tanaka, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-96167-0 · Cited by 32
Xie, Q., Zhang, P., Wang, Y., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958720 · Cited by 35
Jiang, Z., Wu, Y., Miao, Y., Deng, K., Yang, F., Xu, S. J., Wang, Y., You, R., Zhang, L., Fan, Y., et al. (2024) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzae011 · Cited by 33
Yu, L., Wang, S., Liu, J., Yan, W., Han, P., & Tian, D. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119227 · Cited by 31
Zheng, Q., Yang, Q., Zhou, J., Gu, X., Zhou, H., Dong, X., Zhu, H., & Chen, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02033-4 · Cited by 30
Liver cancer: Translating '–omics' results into precision medicine for hepatocellular carcinoma
Sia, D., & Llovet, J. (2017) · Nature Reviews Gastroenterology &Hepatology · doi:10.1038/nrgastro.2017.103 · Cited by 32
Self-citationUpdate on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint
Soylu, N. K. (2020) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-020-00499-5 · Cited by 31
Implications of genetic heterogeneity in hepatocellular cancer
Suresh, A., & Dhanasekaran, R. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.01.007 · Cited by 33
Ning, J., Ye, Y., Shen, H., Zhang, R., Li, H., Song, T., Zhang, R., Liu, P., Chen, G., Wang, H., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101505 · Cited by 33
Ji, S., Cao, L., Gao, J., Du, Y., Zeng, Y., Lou, X., Liu, F., Zhang, Y., Xu, J., Shi, X., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.016 · Cited by 32
Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma
Ihling, C. H., Naughton, B. J., Zhang, Y., Rolfe, A., Frick-Krieger, E., Terracciano, L., & Dussault, I. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00015 · Cited by 30
Juengpanich, S., Topatana, W., Lu, C., Staiculescu, D., Li, S., Cao, J., Lin, J., Hu, J., Chen, M., Chen, J., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32970 · Cited by 30
Papadakos, S. P., Arvanitakis, K., Stergiou, I. Ε., Lekakis, V., Davakis, S., Christodoulou, M., Germanidis, G. S., & Theocharis, S. E. (2023) · Cancers · doi:10.3390/cancers15102795 · Cited by 31
Papadakos, S. P., Ferraro, D., Carbone, G., Frampton, A. E., Vennarecci, G., Kykalos, S., Schizas, D., Theocharis, S. E., & Machairas, N. (2023) · Cancers · doi:10.3390/cancers15123161 · Cited by 31
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Kudo, M. (2021) · Liver Cancer · doi:10.1159/000518584 · Cited by 31
A classification based on tumor budding and immune score for patients with hepatocellular carcinoma
Li, W., Delin, Z., Kefei, Y., Wu, H. M., Jiwei, H., & Zhang, Y. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1672495 · Cited by 29
Kudo, M. (2021) · Cancers · doi:10.3390/cancers13215475 · Cited by 29
Sukei, T., Palma, E., & Urbani, L. (2021) · Cancers · doi:10.3390/cancers13215586 · Cited by 29
Ghidaglia, J., Golse, N., Pascale, A., Sebagh, M., & Besson, F. L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.924824 · Cited by 29
Carone, C., Olivani, A., Valle, R. D., Manuguerra, R., Silini, E. M., Trenti, T., Missale, G., & Cariani, E. (2018) · Liver Cancer · doi:10.1159/000486764 · Cited by 29
Lv, L., Zhao, Y., Wei, Q., Zhao, Y., & Yi, Q. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01298-5 · Cited by 28
Craig, A. J., García‐Lezana, T., de Galarreta, M. R., Villacorta-Martín, C., Gonzalez‐Kozlova, E., Martins-Filho, S. N., von Felden, J., Ahsen, M. E., Bresnahan, E. R., Hernandez‐Meza, G., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009589 · Cited by 29
Self-citationChanges in therapeutic options for hepatocellular carcinoma in Asia
Ogasawara, S., Koroki, K., Kanzaki, H., Kobayashi, K., Kiyono, S., Nakamura, M., Kanogawa, N., Saito, T., Kondo, T., Nakagawa, R., et al. (2021) · Liver International · doi:10.1111/liv.15101 · Cited by 28
Battista, D. D., Zamboni, F., Gerstein, H., Sato, S., Markowitz, T. E., Lack, J., Engle, R. E., & Farci, P. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s325959 · Cited by 28
The Portrait of Liver Cancer is Shaped by Mitochondrial Genetics
Chattopadhyay, M., Jenkins, E. C., Lechuga‐Vieco, A. V., Nie, K., Fiel, M. I., Rialdi, A., Guccione, E., Enrı́quez, J. A., Sia, D., Lujambio, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110254 · Cited by 28
Self-citationHatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10406-8 · Cited by 29
Santagata, S., Rea, G., Castaldo, D., Napolitano, M., Capiluongo, A., D’Alterio, C., Trotta, A. M., Ieranò, C., Portella, L., Maro, S. D., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10537-6 · Cited by 28
Pelizzaro, F., Farinati, F., & Trevisani, F. (2023) · Biomedicines · doi:10.3390/biomedicines11041020 · Cited by 28
Metadata
- Authors
- Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., Losic, B., Waxman, S., Thung, S. N., Mazzaferro, V., Esteller, M., Friedman, S. L., Schwartz, M., Villanueva, A., & Llovet, J. M.
- Affiliations
- Tisch Cancer Institute (US)
- Hospital Clínic de Barcelona (ES)
- University of Milan (IT)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 153
- Issue
- 3
- Pages
- 812-826
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC12166766
- OpenAlex
- W2626033245
- Cited by
- 976
- References
- 46
- Citations by year
- 2026: 65 · 2025: 82 · 2024: 124 · 2023: 136 · 2022: 155 · 2021: 188 · 2020: 104 · 2019: 72 · 2018: 41 · 2017: 9
- FWCI
- 27.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (acceptedVersion, cc-by-nc-nd)
- Funders
- Tisch Cancer Institute (P30 CA196521)
- US Department of Defense (CA150272P3)
- European Commission Framework Program 7 (259744)
- Horizon 2020 Program (667273–2)
- Asociación Española Contra el Cáncer
- Samuel Waxman Cancer Research Foundation
- Spanish National Health Institute (SAF2013–41027)
- Grup de Recerca Consolidat–Recerca Translacional en Oncologia Hepàtica
- AGAUR (SGR 1162)
- European Commission HEPCAR
- Onlus Prometeo
- Hepato-Oncology Research Project
- Istituto Nazionale Tumori
- National Cancer Institute
- IRCCS Foundation
- Juan de la Cierva Fellowship
- Associazione Italiana per la Ricerca sul Cancro
- Italian Ministry of Health
- National Institutes of Health (R01DK56621)
- American Association
- Liver Diseases Foundation Alan Hofmann Clinical and Translational Award
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, tumor immune microenvironment, immune cell infiltration, PD-1, T cell exhaustion, TGF-β1, chromosomal abnormalities, cancer mutations, tumor-infiltrating immune cells, immune checkpoint inhibitors, tumor subtypes, gene expression profiling, non-negative matrix factorization, tides
- MeSH terms
- Aged, Female, Carcinoma, Hepatocellular, Humans, Immune Tolerance, Immunohistochemistry, Liver Neoplasms, Male, Middle Aged, Mutation, Signal Transduction, Gene Expression Regulation, Neoplastic, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, DNA Methylation, beta Catenin, Transforming Growth Factor beta1, Adaptive Immunity, Tumor Microenvironment, Transcriptome, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
